Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Monopar Therapeutics Inc. (MNPR) had Return on Tangible Equity of -28.32% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-15.59M |
|
-- |
|
-- |
|
$16.16M |
|
$-16.16M |
|
$0.58M |
|
$-15.59M |
|
$-15.59M |
|
$-15.59M |
|
$-15.59M |
|
$-15.59M |
|
$-15.59M |
|
$-16.16M |
|
$-16.16M |
|
3.79M |
|
3.79M |
|
$-4.11 |
|
$-4.11 |
|
| Balance Sheet Financials | |
$60.29M |
|
-- |
|
-- |
|
$60.29M |
|
$5.25M |
|
-- |
|
-- |
|
$5.25M |
|
$55.04M |
|
$55.04M |
|
$55.04M |
|
6.10M |
|
| Cash Flow Statement Financials | |
$-6.40M |
|
$-14.34M |
|
$59.29M |
|
$7.27M |
|
$45.82M |
|
$38.55M |
|
$1.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.47 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.40M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.32% |
|
|
Return on Tangible Equity |
-28.32% |
-25.85% |
|
-28.32% |
|
$9.02 |
|
$-1.69 |
|
$-1.69 |
|